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Abstract  
Stable isotope labelling of lipid precursors coupled with mass spectrometry-based lipidomic 
analyses and determination of isotope enrichment in substrate, intermediate and product pools 
provide the parameters needed to determine absolute flux rates through lipid pathways in 
vivo.  Here, as an illustration of the power of such analyses we investigated lung 
phosphatidylcholine (PC) synthesis in Surfactant Protein-D (SP-D) null mice.  These animals 
develop emphysema, foamy alveolar macrophages and an alveolar lipoproteinosis with 
increasing age.  We used the incorporation of methyl-9-[
2
H] choline chloride coupled with 
ESI-MS/MS to quantify absolute rates of lung surfactant PC synthesis and secretion in an SP-
D
-/-
 mouse model, together with an analysis of the molecular specificity of lung PC synthesis.  
PC synthetic rates were comparable in control (0.52 μmoles/lung/h) and SP-D-/- (0.69 
μmoles/lung/h) mice, as were rates of surfactant PC secretion (29.8 and 30.6 nmoles/lung/h 
respectively).  Increased lung PC in the SP-D
-/-
 mouse was due to impaired catabolism, with a 
rate of accumulation of 0.057 μmoles/lung/h.  The relatively low rates of surfactant PC 
secretion compared with total lung PC synthesis were compatible with a suggested ABCA1-
mediated basolateral lipid efflux from alveolar type II epithelial cells.  Finally, PC molecular 
species analysis suggested that a proportion of newly-synthesised PC is secreted rapidly into 
the lung air spaces in both control and SP-D
-/-
 mice before significant PC acyl remodelling 
occurs.   
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1. Introduction 
Use of stable isotope labelling of lipid precursors in conjunction with detailed, mass 
spectrometry-based, lipidomic analyses has yielded powerful methodologies for molecular 
level analysis of the specificity and dynamics of lipid synthesis in vivo and in vitro (Postle et 
al 2007, Postle and Hunt 2009).  When combined with determination of isotope enrichment 
within substrate pools these data further permit calculation of absolute flux rates through 
pathways and even individual molecular species of lipids (Pynn et al 2011).  Such tools, in 
addition to probing normal developmental, nutritional or pathology-based perturbations in 
lipid metabolism, can also provide greater insight into unexpected 
derangements/dysregulations of lipid metabolism that may accompany specific gene targeted 
modifications. 
  
An illustrative example is provided by surfactant protein D (SP-D), a member of the collectin 
family of carbohydrate pattern recognition host defence proteins, synthesised and secreted by 
the lung alveolar epithelium (Persson et al 1988), but also by many other epithelial surfaces 
(Madsen et al 2000).  In addition to its ability to opsonise and aggregate bacteria (Kuan et al 
1992, Restrepo et al 1999) and to bind viral particles and fungi (Hartshorn et al 1994, 
Schelenz et al 1995), studies in a variety of SP-D null mice have highlighted an initially 
unexpected role for SP-D both in the maintenance of the integrity of alveolar structure and in 
the regulation of pulmonary surfactant phospholipid metabolism.  SP-D
-/-
 mice develop a 
progress emphysema-like destruction of alveolar septa with age characterised by a 
progressive alveolar lipoproteinosis and the accumulation of large foamy macrophages (Botas 
et al 1998, Korfhagen et al 1998).  Incorporation [
3
H]palmitate and [
14
C]choline into SP-D
-/-
 
mouse lung tissue and bronchoalveolar lavage (BALF) disaturated phosphatidylcholine (Sat-
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PC) has previously been described (Ikegami et al 2000), with increased labelling of lung 
tissue PC and accumulation of incorporated label in BALF PC up until 72h incubation.  
These results were interpreted as decreased PC catabolism in the SP-D
-/-
 mouse compared 
with control mouse lungs.   
 
Many studies have used Sat-PC analysis as a surrogate for dipalmitoylphosphatidylcholine 
(DPPC, PC16:0/16:0), the major surface-tension lowering component of lung surfactant; the 
fundamental importance of DPPC for optimal function of human lung surfactant was 
established soon after the identification of surfactant deficiency as the primary cause of 
respiratory distress syndrome in preterm infants (Avery and Mead 1959, Klaus et al 1961).  
SAT-PC has typically been analysed as the residue after oxidation of surfactant lipid extracts 
with OsO4 (Mason et al 1976).  In this experimental approach, OsO4 complexes with double 
bonds in the unsaturated PC species leaving disaturated phospholipids as the chloroform-
soluble residue.  The OsO4 technique has the advantages of being rapid, amenable to analysis 
of relatively large numbers of samples and providing a simple result.  However, SAT-PC 
analysis is not specific for DPPC, but also includes other PC species such as 
palmitoylmyristoyl PC (PC16:0/14:0) (Hunt et al 1991), which can in turn be a significant 
surfactant component, for instance in the suckling post-natal rat (Bernhard et al 2007).  This 
example illustrates the importance of the distribution of individual phospholipid molecular 
species for studies of surfactant metabolism and function.  We have previously demonstrated 
the usefulness of surfactant phospholipid molecular species molecular species analysis in a 
variety of respiratory diseases, including asthma (Wright et al 2000), cystic fibrosis (Postle et 
al 1999) and paediatric acute lung injury (Todd et al 2010). 
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Numerous studies have detailed the importance of acyl remodelling mechanisms in the 
synthesis of DPPC (Stymne and Stobart 1985, Batenburg et al 1978, Caesar et al 1991).  Up 
to 50% of lung DPPC is not synthesised directly from diacylglycerol (DAG), but is 
remodelled from other PC species by the sequential actions of phospholipase and 
acyltransferase enzymes.  These analyses have shown an initial synthesis of unsaturated PC, 
typically palmitoyllinoleoyl PC (PC16:0/18:2) or palmitoyloleoyl PC (PC16:0/18:1), their 
subsequent conversion to 1-palmitoyl lysoPC (LPC16:0) by the action of a phospholipase A2, 
followed finally by re-esterification to DPPC by the addition of palmitoyl-CoA, catalysed by 
lysoPC acyltransferase (LPCAT) (Okuyama et al 1983).  Indeed, the critical importance of 
LPCAT for surfactant function has recently been highlighted by the demonstration that the 
null mutation is fatal in neonatal mice (Chen et al 2006). 
 
One final factor in surfactant metabolism that has rarely been considered in detail is the 
temporal relationship between mechanisms of phospholipid synthesis and the molecular 
specificity of surfactant secretion from the type II cell.  The assumption of studies which 
typically involve pre-labelling surfactant PC for 24 hours followed by hormonal stimulus of 
secretion is that these are linear processes.  Their inherent implication is that surfactant PC is 
synthesised de novo, acyl remodelled and packaged into lamellar bodies to acquire its mature 
equilibrium composition before lamellar body contents are secreted into the alveolar lumen.  
This assumption has been challenged by the use of the stable isotope methyl-9-[
2
H] choline 
administered to human volunteers and subsequent analysis by electrospray ionisation mass 
spectrometry (ESI-MS) of methyl-9-[
2
H] incorporation into PC molecular species of 
sequential induced-sputum samples Bernhard et al 2004).  This analysis showed a time-
dependent redistribution of incorporated stable isotope label towards DPPC, strongly 
suggesting both that a proportion of newly-synthesised surfactant PC is secreted before acyl 
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remodelling is complete and that the processes of acyl remodelling and secretion must be 
independently regulated. 
 
We have used the same ESI-MS methodology to investigate the mechanisms underlying the 
dysregulation of surfactant PC metabolism in an SP-D
-/-
 mouse model.  Here we report the 
relative contributions of altered PC synthesis and turnover to the accumulation of alveolar 
phospholipids in the SP-D
-/-
 mouse and whether this phospholipid accumulation is 
accompanied by any alteration to the molecular specificity of surfactant PC synthesis or acyl 
remodelling. 
  
2. Materials and methods 
2.1 Animal labelling 
Standard homologous techniques were used to generate mice deficient in SP-D as previously 
described. The deficient mice were imported from the laboratory of Professor Sam Hawgood, 
University of California, San Francisco. The SP-D knock-out mice, back-crossed more than 
10 generations into a C57BL/6 background were fed ad libitum and housed in isolators in a 
pathogen free environment.  Pathogen free C57BL/6 wild-type age and sex, matched controls 
were obtained from Harlan-OLAC (Shaw’s Farm, Bicester, Oxfordshire, UK). Eight week 
old female were kept in a normal light-dark cycle and had free access to pelleted food and 
water. Animals received appropriate human care according to criteria outlined in the NIH 
guidelines for the care and use of laboratory animals. Animals received 100μl intraperitoneal 
injections of methyl-9-[
2
H] choline chloride (10mg/ml solution in sterile physiological saline) 
and were sacrificed at 1.5, 3, 6 and 24 hours (n = 5 per time point/group) after labelling. Mice 
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were killed by carbon dioxide asphyxia, their tracheas rapidly canulated, lungs lavaged in situ 
four times with 0.9% (w/v) saline and the volume recorded.  Recovered bronchoalveolar 
lavage fluid (BALF) was placed on ice and lung parenchyma was rapidly dissected away 
from main bronchi and flash frozen in liquid nitrogen.  Frozen lung tissue was transferred to 
pre-weighed sample vials, lung weights determined and samples then stored at -80 
o
C until 
extraction.  BALF was centrifuged at 400 x g x 10 min at 4 
o
C to pellet alveolar macrophages 
and supernatants stored at -80 
o
C until extraction.  
 
2.2 ESI-MS analysis of phosphatidylcholine and choline phosphate 
Frozen lavaged lungs were homogenised in 3 ml of 0.9% saline using an Ultra-Turrax 
homogeniser (Janke & Kunkel, IKA-Labortechnik, Staufen, Germany). Aliquots (800 μl) of 
the lung homogenates or BALF were lipid extracted with chloroform and methanol (Bligh 
and Dyer 1959) after adding dimyristoyl PC (PC14:0/14:0) as internal standard.  Trace 
amounts of endogenous PC14:0/14:0 would contribute a maximum quantification error of 
0.6% and 1.3% for lung tissue and BALF respectively, values within the experimental error 
of the analysis. The chloroform-rich lower phases were recovered, dried under nitrogen gas 
and stored at -20 
o
C for ESI-MS analysis.  The upper phases from the tissue extracts were 
collected and lyophilised, and choline phosphate isolated according to the following method 
(Burge et al 1993). The residues were dissolved in 1ml 0.05% ammonia/methanol (1:9, v/v), 
sonicated for 2 minutes and centrifuged at 13,000 x g x 30 secs to remove particulates. The 
supernatants were applied to aminopropyl solid phase cartridges (Varian Inc. Palo Alto, 
USA) previously conditioned with 1 ml 0.05% ammonia/methanol (1:9, v/v). Loaded 
cartridges were then washed with 1ml (0.05% ammonia/methanol (1:9, v/v) and choline 
phosphate eluted with 1.5ml 0.05% ammonia: 6% (w/v) NH4HCO3: methanol (1:1:4, v/v). 
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The eluates were dried under nitrogen gas and re-suspended in methanol (100μl) for analysis 
by ESI-MS/MS.  
 
PC species were quantified using a Waters Micromass Quattro Ultima triple quadrupole mass 
spectrometer (Micromass, Wythenshaw, UK) equipped with an electrospray ionisation 
interface. Samples were dissolved in methanol:chloroform:water: 25% NH4OH 
(7:2:0.8:0.2,v/v) and introduced into the mass spectrometer by direct infusion. Collision gas-
induced dissociation (CID) using argon gas produced protonated phosphocholine head group 
fragments with m/z = +184 corresponding to endogenous PC and m/z = +193 for PC 
synthesised via the CDP-choline pathway (Hunt et al 2001). Endogenous PC molecular 
species were quantified from diagnostic precursor ion scans of the m/z =184 fragment ion 
(P184) while newly synthesised PC was quantified from comparable diagnostic precursor ion 
scans of the m/z=193 fragment ion (P193). Endogenous and methyl-9-[
2
H] labelled choline 
phosphate were quantified by ESI-MS/MS operated in the multiple reaction monitoring 
(MRM) mode, monitoring the transition from the precursor ions m/z = + 183.8 and m/z = 
+192.8 to product fragment ions m/z = + 85.8 and m/z = + 94.8 respectively using a dwell 
time of 0.1 seconds. 
 
PC molecular species and incorporation of methyl-9[
2
H] choline were calculated using self-
extracting Excel macro programmes developed in house.  MS spectra were smoothed, 
baseline-subtracted, converted to centroid format and exported to individual Excel sample 
files.  These were imported into the analyser programme and corrected for the [M+1]
+ 
and 
[M+2]
+
 ions generated by the approximately 1% natural abundance of 
13
C.  The fractional 
incorporations of methyl-9[
2
H] choline into individual PC molecular species were then 
calculated relative to the total abundance given by Σ(P184 + P193).   
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3. Results 
3.1 Methyl-9-[
2
H] choline incorporation into lung and BALF 
Choline is incorporated into PC by the CDP:choline pathway, whereby it is converted first to 
choline phosphate and then CDP:choline by the sequential actions of choline kinase and 
CTP:cholinephosphate cytidylyltransferase (CCT).  CDP:choline then complexes with DAG 
by the action of cholinephosphotransferase to form PC.  The composition of newly 
synthesised PC will reflect that of the DAG substrate and, if the CDP:choline is labelled with 
deuterium atoms, these will be retained in the synthesised PC.  ESI-MS can then readily 
distinguish between endogenous and newly-synthesised PC molecules by precursor scans of 
respectively m/z 184 (P184) and 193 (P193), these being the CID-generated fragment ions of 
choline phosphate and methyl-9-[
2
H] choline phosphate.  This is shown clearly in Figure 1, 
which details P184 and P193 scans of total lipid extracts from a lavaged lung (panels A and 
B) of a control mouse 1.5 hours after the i.p. injection of 1 mg methyl-9-[
2
H] choline chloride.  
Both spectra have been normalised to the highest abundance ion peak displayed; the 
respective fractional incorporations are shown below in Figure 2.  Importantly, although 
newly synthesised and endogenous PC had relatively similar compositions, these were not 
identical. For example, the proportion of PC16:0/18:2 and PC16:0/18:1 were higher in newly 
synthesised PC compared with endogenous PC, but there was negligible incorporation into 
the corresponding stearoyl species (PC18:0/18:2 and PC18:0/18:1). 
 
The fractional incorporations of methyl-9-[
2
H] choline incorporation into PC were calculated 
for the sum of the 19 molecular species that individually contributed greater than 1 mole % of 
total PC.  This value was given by equation 1: 
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Fractional intensity =    (ΣP193 x 100)    %, where ΣP193 and ΣP184 are sums of the  
   (ΣP193 + ΣP184) 
respective ion intensities after correction for 
13
C isotope abundance and differential CID 
fragmentation.  Lung fractional incorporation was maximal at 6h for control and at 3h for SP-
D
-/-
 mice and then declined by 24h for both groups (Fig 2A).  At all time points, the extent of 
the fractional enrichment for the SP-D
-/-
 mouse was consistently about half that of control 
mice (Fig 2A).  Incorporation into BALF PC was measureable by 1.5h and then increased 
progressively until 24h; enrichment of BALF PC was again much lower in the SP-D
-/-
 
compared with control mice at all time points (Fig 2B). These comparisons are somewhat 
misleading, however, as total PC concentration in the lavaged SP-D
-/-
 mouse lung was higher 
than in control mouse lung (2.20±0.69 vs 1.54±0.26 μmoles/lung, n=20, p<0.001), with 
corresponding values for BALF PC being 0.54±0.22 and 0.26±0.12 μmoles/lavage (p<0.001).  
There was proportionally more PC recovered in the lavage fraction in the SP-D
-/-
 mouse 
(19.95±5.64) than in the control mouse (13.07±3.48 % total lung PC, p<0.001).  Taking these 
differences into account, rates of incorporation/lung of methyl-9-[
2
H] choline were more 
comparable between the two groups. 
 
3.2 Calculation of lung PC synthesis and turnover 
The extent of incorporation of a labelled substrate is the product of the measured enrichment 
corrected for label enrichment in the substrate.  Consequently, some of the incorporation 
discrepancy between SP-D
-/-
 and control mice could have been due to a difference in 
substrate enrichment.  This was indeed the case as enrichment of methyl-9-[
2
H] choline 
phosphate (CP), the substrate for CCT, was consistently lower in lavaged lungs from SP-D
-/-
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compared with control mice (Fig 3).  We assume that, although the SP-D
-/-
 mice were fully 
back-crossed, a mouse strain difference with the control C56BL mice explained the lower 
enrichment of substrate methyl-9-[
2
H] choline phosphate. It was unlikely to be a direct 
consequence of absence of SP-D in the lungs as enrichment of methyl-9-[
2
H] choline 
phosphate was similarly lower at all time points in parallel analysis of mouse spleen from SP-
D
-/-
 compared with control mice (results not shown). 
 
Knowledge of fractional enrichments of PC and choline phosphate, lung weight and total 
lung PC concentration enabled us to estimate apparent absolute amounts of lung PC 
synthesised at each time point (t) from the equation 2: 
 
      
 
Initial rates of lung PC synthesis were calculated over the first 3h after administration of 
methyl-9-[
2
H] choline chloride (Fig 4).  More intermediate time points would have been 
required for an accurate correlation, but using the results at 1.5 and 3h suggested that lung PC 
synthesis was slightly faster in the SP-D
-/- 
mouse (0.69 μmoles/lung/h) compared with control 
mice (0.52 μmoles/lung/h).  They also suggested that analysis of a single time point at 3h 
would provide a reasonable assessment of the rate of lung PC synthesis for both groups of 
mice.  The amount of PC synthesised by the control mouse lungs reached a plateau value of 
1.71±0.31 μmoles/lung between 6 and 24h, which was in close agreement with the analysed 
lung PC content (1.54±0.26 μmoles/lung, Fig 4, lower dotted horizontal line).  This plateau 
PC enrichmentt 
CP enrichmentt 
[PC]t 
weight 
PC synthesist = x μmoles/lung 
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value represented the equilibrium between PC synthesis by the lungs and loss of PC from 
lung tissue by a combination of surfactant secretion, PC catabolism within the lungs and 
potentially from basolateral secretion of unsaturated species from type II pneumocytes into 
the circulation (Zhou et al 2004, Agassandian et al 2004).  By definition, of course, these 
values in an equilibrium state must be identical.   
 
The similar calculation for the SP-D
-/- 
mouse gave a very different result, in that after the 
initial linear synthesis over the first 3h, the apparent rate of lung PC synthesis continued to 
increase up until 24h to a value greater than measured total lung PC content for this mouse 
(2.20±0.69 μmoles/lung, Fig 4, upper dotted horizontal line).  In reality, of course, it is not 
possible for the lungs to contain more synthesised PC than total PC content, and this 
discrepancy was a direct reflection of decreased lung PC catabolism in the SP-D
-/- 
mouse 
coupled with the progressive decline with time of isotope enrichment in the choline 
phosphate substrate pool.  Increased residence of PC synthesised at earlier incubation time 
points, when corrected for the lower choline phosphate enrichment at the later times, would 
lead to this apparent anomaly.  More time points would be required for an accurate 
assessment from this analysis of the rate of impaired lung PC catabolism in the SP-D
-/- 
mouse, but an upper value of 0.057 μmoles/lung/h can be estimated from the results between 
6 and 24h as a measure of the rate of accumulation of lung PC.  This is almost certainly an 
over-estimate, but illustrates how a relatively small imbalance between synthesis and 
catabolism is sufficient to account for the slow accumulation of PC in the SP-D
-/-
 mouse lung.  
 
3.3 PC secretion and turnover in BALF 
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Newly synthesised PC (% total methyl-9-[
2
H] choline incorporation) was detectable in BALF 
at 1.5h (Fig 5); extrapolation of the data suggested that the lag time for secretion of newly 
synthesised surfactant PC was just under one hour (mean 0.94h).  Initial accumulation of 
label between 1.5 and 6h was slightly greater for SP-D
-/- 
mice (1.47 % total incorporation/h) 
than for control mice (1.25 % total incorporation/h), but this difference was not significant 
until 24h (Fig 5).  These proportions of secreted PC at 24h were comparable to the 
distributions of endogenous PC in BALF. Correcting this percentage secretion for substrate 
choline phosphate enrichment, the apparent rates of PC secretion for the first 6h after label 
administration were identical for SP-D
-/- 
mice (30.6 nmoles/h) and control mice (29.8 
nmoles/h) (Fig 6).  
 
3.4 Specificity of surfactant phosphatidylcholine synthesis 
In addition to estimates of total PC flux, ESI-MS facilitated the analysis of the molecular 
specificity of acyl remodelling in surfactant PC synthesis and secretion.  Figure 7 shows the 
relative incorporations of methyl-9-[
2
H] choline into BALF PC molecular species.  Species 
characteristic of lung surfactant (PC16:0/16:0 and PC16:0/16:1) were relatively under 
represented in newly secreted PC at 1.5 and 3h, and then increased to equilibrium 
endogenous values by 24h.  By contrast, PC species more characteristic of cell membrane 
(expressed in figure 7 as the sum of the unsaturated species PC16:0/18:1, PC16:0/18:2, 
PC18:0/18:1 and PC16:0/20:4) were relatively enriched in newly secreted BALF PC and 
declined progressively with time.  This analysis not only demonstrated that acyl remodelling 
mechanisms were active in lung PC synthesis, and were essentially identical for SP-D
-/-  
and 
control mice,  but that the processes of acyl remodelling, lamellar body assembly and 
secretion do not form a linear sequence.  If these processes were linear, implying that all 
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newly-synthesised surfactant PC had to achieve the mature composition before secretion, 
then all newly synthesised and secreted surfactant PC would have been expected to display 
the same composition at all time points after label administration, and this was clearly not the 
case. 
 
4. Discussion 
Total lung phospholipid content of the SP-D
-/-
 mouse has been reported to increase 
progressively compared with control mice up until at least 18 weeks (Botas et al 1998) after 
birth.  As we wished to characterise the mechanisms responsible for this phenomenon, we 
chose to study mice at 8 weeks of age when the lung lipid accumulation in the SP-D
-/-
 mouse 
is first apparent. The incorporation results presented in Figs 2, 3 and 4 represent a novel 
approach to the analysis of synthesis and turnover of lung PC.  Correction of lung PC methyl-
9-[
2
H] enrichment (Fig 2) both for lung PC concentration and for choline phosphate 
enrichment demonstrated a the linear rate of PC synthesis calculated over the first 3h which 
was slightly higher for SP-D
-/-
 compared with control mice (Fig 4).  For control mice, which 
regulate a constant lung PC concentration, the rate of PC catabolism and/or export must equal 
this rate of synthesis, giving a turnover time of 3.19h calculated by dividing lung PC 
concentration by synthetic rate.  One consequence of this conclusion is that, for analyses at 
6h and 24h, all lung PC was effectively synthesised in the proceeding 3h period.  This 
interpretation is supported by the observation that the total amount of newly synthesised PC 
(μmole/lung) reached a plateau from 3-24h that was very close to the lung PC concentration 
calculated from the P184 scan. In contrast, comparable analysis for the SP-D
-/-
 mouse 
demonstrated that the rates of lung PC synthesis and loss were not at equilibrium (Fig 4).   
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These calculations also provide novel insights into the relative dynamics of PC turnover in 
whole lung and in lung surfactant. The rate of PC turnover in BALF in control mice was 9 
nmoles/h, while the rate of lung PC turnover was 57 nmoles/h.  This observation shows 
clearly that metabolism of secreted alveolar surfactant makes a relatively minor contribution 
to the overall loss of newly synthesised PC from the lungs.  It is unlikely that phospholipase 
A2-mediated hydrolysis, for instance, is a major contributor to mouse lung PC catabolism, as 
concentration and incorporation of methyl-9-[
2
H] choline into lung lysoPC remained low 
throughout the 24h labelling period (results not shown).  The most likely mechanism 
responsible for loss of newly synthesised PC from the lung is export of PC from the type II 
pneumocyte into the circulation and/or lymph fluid.  This has been reported to be mediated 
by ABCA1, with ApoA1 as the acceptor , is stimulated to compensate for increased lung PC 
synthesis (Zhou et al 2004) and is relatively specific for longer acyl chain unsaturated PC 
species.  The importance of shorter acyl chain length for selection of PC species to be 
packaged into lamellar bodies and secreted surfactant (Postle et al 2006) is shown clearly by 
the increased fractional synthesis of PC16:0/16:1 with time.  The significance of this 
mechanism for removal of PC and cholesterol from lung is shown clearly by the elevated 
lung lipid content and respiratory distress experienced by ABCA1 deficient mice (Bates et al 
2005). 
 
Finally, the pattern of surfactant PC synthesis and secretion into BALF also has important 
implications for understanding of mechanisms regulating the molecular specificity of 
surfactant PC composition.  The importance of acyl remodelling mechanisms in the synthesis 
of surfactant PC16:0/16:0 has long been appreciated (Okuyama et al 1983), and redistribution 
with time of the incorporated methyl-9-[
2
H] choline headgroup from an initially synthesised 
unsaturated PC towards PC16:0/16:0 was indeed observed as expected in both SP-D
-/- 
and 
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control mice (results not shown).  The novel and significant observation here (Fig 7) was that 
a similar redistribution of headgroup methyl-9-[
2
H] choline label was also observed for both 
groups of mice. This demonstrates that newly-synthesised PC is rapidly packaged into 
lamellar bodies and secreted into the alveolus before acyl remodelling processes are 
complete, in agreement with our previous analysis of the specificity of methyl-9-[
2
H] choline 
incorporation into induced sputum PC in adult human volunteers (Bernhard et al 2004).  The 
fundamental implication from this observation is that assembly of PC in lamellar bodies 
followed by secretion is not a completely linear process.   
 
The rapid synthesis and turnover of total PC in mouse lung is characteristic of a biological 
system with a requirement to respond rapidly to altered physiological conditions.  As with 
enzyme protein turnover (Walker 1983), rapid degradation with a high turnover is a pre-
requisite for the lungs to be able to increase surfactant PC synthesis rapidly in response, for 
instance, to alveolar stretch (Torday and Rehan 2002).  Moreover, this analysis suggests that 
this mechanism for bulk lung PC turnover is not significantly altered in the SP-D
-/-
 mouse, 
supporting previous conclusions that the accumulation of lung and alveolar PC in the SP-D
-/-
 
is a consequence of impaired catabolism.  Studies of the catabolism of tracer amounts of 
[
3
H]PC16:0/16:0 administered together with exogenous surfactant strongly suggest that, 
unlike in the granulocyte-macrophage colony-stimulating factor deficient mouse that also 
develops an alveolar lipidosis, uptake and degradation of surfactant PC by alveolar 
macrophages is not deficient in the SP-D
-/-
 mouse (Ikegami et al 2000).  Consequently, 
uptake and processing of surfactant PC as part of alveolar surfactant recycling are the most 
likely causes of the specific PC catabolism defect in the SP-D
-/-
 mouse. 
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Legends to Figures  
 
Figure 1.  Electrospray ionisation mass spectrometric analysis of endogenous and newly 
synthesised mouse lung phosphatidylcholine. A control mouse was injected i.p. with 1mg 
methyl-9-[
2
H] choline chloride and killed 1.5h later.  Lungs were lavaged, homogenised and 
extracted as described in the methods section.  Endogenous PC was selectively detected by 
diagnostic precursor scan of the fragment ion m/z 184
+ 
(panel A)
 
and incorporated stable 
isotope by precursor scan of m/z 193
+
 (panel B).  Each spectrum is normalised to 
PC16:0/16:0, the most abundant species on display.  PC species with the same fatty acid 
distributions are 9 amu higher in the newly synthesised 9-[
2
H]PC. Spectral data for Panel B 
was collected for x3 that for Panel A. 
 
Figure 2. Incorporation of methyl-9-[2H] choline into mouse lung and bronchoalveolar 
lavage phosphatidylcholine in vivo.  SP-D
-/-
 mice (squares) and C57BL6 control mice 
(circles) were all injected with 1mg methyl-9-[
2
H] choline chloride and sacrificed at the 
indicated times. Total lipid was extracted from lavaged lungs (panel A) and bronchoalveolar 
lavage fluid (panel B) and analysed by ESI-MS/MS as P184
+
 and P193
+
 scans.  Fractional 
enrichment of the methyl-9-[
2
H] choline-labelled PC was determined after correction for 
13
C 
and differential fragmentation as % total PC in the extract.  Data is presented as mean±S.D., 
n=3-5. 
 
Figure 3. Fractional enrichment of choline phosphate from mouse lung. Choline 
phosphate was isolated from the aqueous fraction of the lipid extracts of mouse lung 
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homogenate shown in figure 2 and analysed by MRM monitoring of the 183.8→85.8 
transition for endogenous and the 192.8→94.8 transition for stable isotope labelled choline 
phosphate. Data is presented as mean±S.D., n=3-5, * p<0.01. 
 
Figure 4. Synthesis of phosphatidylcholine by mouse lung in vivo. The enrichment data 
presented in figure 2 was corrected for total PC content and the fractional enrichment of 
methyl-9-[
2
H] choline phosphate of lavaged lung from SP-D
-/-
 mice (squares) and C57BL6 
control mice (circles) to give an estimate of the apparent concentration of newly synthesised 
PC in lavaged lung (μmole/lung, mean±S.D., n=3-5).  Rates of synthesis were calculated 
from the data at 1.5h and 3h (dashed lines).  Total mean lung PC is shown by the horizontal 
dotted lines. 
 
Figure 5. Secretion of newly synthesised phosphatidylcholine into bronchoalveolar 
lavage fluid. Appearance of methyl-9-[
2
H] choline label in BALF PC was calculated as a 
percentage of the sum of incorporation of the stable isotope into lavaged lung and BALF for 
SP-D
-/-
 mice (squares) and C57BL6 control mice (circles).  The proportion of total 
endogenous lung PC recovered in BALF is shown for comparison.  Results are presented as 
mean±S.D., n=3-5, * p<0.05. 
 
Figure 6. Phosphatidylcholine secretion by mouse lung. The apparent concentration of 
newly synthesised PC recovered in BALF was calculated as nmoles/total recovered lavage 
fluid. Total mean BALF PC is shown by the horizontal dotted lines. Results are presented as 
mean±S.D., n=3-5, * p<0.05. 
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Figure 7. Distribution of incorporated methyl-9-[
2
H] choline label in newly synthesised 
phosphatidylcholine molecular species from bronchoalveolar lavage fluid. Results are 
presented for PC species characteristic of lung surfactant (circles, PC16:0/16:0; squares, 
PC16:0/16:1) and for the sum of PC species more characteristic of cell membranes (triangles, 
ΣPC16:0/18:1, PC16:0/18:2, PC18:0/18:1, PC16:0/20:4).  Data was calculated as a 
percentage of total incorporation into identified PC species, mean±S.D., n=3-5.  
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 We investigate lung PC accumulation in SP-D null mice with a stable isotope 
label 
 Lipidomic analyses can show absolute rates of PC synthesis and secretion 
 PC accumulation in SP-D null lungs is due to impaired lipid catabolism 
 Excess lung PC synthesis is consistent with ABCA1-mediated basolateral lipid 
efflux 
 A proportion of newly synthesised PC is rapidly secreted without remodelling 
*Highlights
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Apical
membrane
Basal
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Type II cell
Basolateral export
Model of phosphatidylcholine synthesis and turnover in mouse alveolar type II cells
PC synthesis, alveolar secretion, turnover via macrophage (x) or type II cell (29.8-x) 
and extrapulmonary transport must balance at equilibrium.  Since PC synthesis is >10 
x alveolar turnover (520 nmoles/lung/h vs 29.8 nmoles/lung/h), export of excess PC is 
essential.  Observed PC saturation may result in part from selective export of 
unsaturated PC.  Implicit in this model is a recognition that lung is a significant extra-
hepatic source of circulating, PUFA-enriched PC.
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